Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
The BTK inhibitor ibrutinib is used to treat chronic lymphocytic leukaemia, however some patients develop resistance to the drug. Here, the authors use genomic analyses to examine the clonal evolution of 5 patients that develop resistance to ibrutinib.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2016-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms11589 |